P  - Caution when used during pregnancy

Molecule Info

Indication & Dosage Oral
Vitamin K deficiency due to drugs or malabsorption
Adult: 10-40 mg daily. 
Adult: Up to 5 mg may be used. Dose depends on INR and degree ofhaemorrhage. 
Prophylaxis of vitamin K deficiency bleeding in neonates
Child: Neonate: 0.5-1 mg, given as a single dose via IM inj. Alternatively, 2 mg may be given orally, followed by a 2nd dose of 2 mg after 4-7 days. 
Adult: 0.5-5 mg via slow IV inj. Dose depends on INR and degree of haemorrhage. 
Vitamin K deficiency bleeding in neonates
Child: Infant: 1 mg by IV/IM/SC inj, further doses may be given if necessary
Administration May be taken with or without food.
Contraindications Hypersensitivity.
Special Precautions Increased risk of severe haemolytic anaemia in neonates after large doses; severe hepatic impairment; pregnancy. Premature neonates weighing <2.5 kg.
Adverse Drug Reactions Anaphylaxis, dyspnoea, cyanosis, pain, swelling, phloebitis at the Inj site, diaphoresis, dizziness, hypotension (rare), allergic reactions after SC and IM inj.
Drug Interactions Decreased effect of oral anticoagulants. Please consult detailed drug interactions before prescribing.
Pregnancy Category (US FDA) Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Storage Intramuscular: Store at 15-30°C. Intravenous: Store at 15-30°C. Oral: Store at 15-30°C. Parenteral: Store at 15-30°C.
Pharmacology Phytomenadione promotes hepatic synthesis of clotting factors. It is a naturally occurring compound that is used to prevent and treat haemorrhages related to vitamin K deficiency.
Absorption: Requires bile for absorption in GI tract.
Distribution: Mainly in the liver.
Metabolism: Rapidly metabolised to glucuronide and sulfate conjugates.
Excretion: In bile and urine as metabolites.
ATC Classification B02BA01 - phytomenadione; Belongs to the class of vitamin K. Used in the treatment of hemorrhage.

Brand/Product Info

Total Products : 7       
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
BABYKION Oral/IM/IV Chemist Laboratories Ltd. Phytomenadione 2mg/0.2ml Injection 2mg amp x5's: 100.00 MRP
DINAKION-10 Oral/IM/IV Drug International Ltd Phytomenadione 10mg/1ml Injection 10mg amp x5's: 225.00 MRP
DINAKION-MM Drug International Ltd Phytomenadione 2mg/0.2ml Injection 2mg amp x5's: 99.45 MRP
Injection K MM Incepta Pharmaceuticals Limited Phytomenadione 10mg/1ml bile acid/lecithin mixed-micelle solution Injection Adult 1x5's:MRP 229.3 Tk
Injection K MM Paed. Incepta Pharmaceuticals Limited Phytomenadione 2mg/0.2ml bile acid/lecithin mixed-micelle solution Injection Paediatric 1x5's:MRP 99.45 Tk
K-ONE MM Square Pharmaceuticals Ltd. Phytomenadione 2mg/0.2 ml IM/IV/Oral Injection 1x3's: 59.82 MRP
KONAKION MM Roche Bangladesh Limited Phytomenadione 2mg/0.2ml, 10mg/1ml Injection 5's each: 551.00 & 575.00 MRP

Gen. MedInfo

Why is this medication prescribed?

Phytomenadione (Vitamin K) is a vitamin found in leafy green vegetables, broccoli, and Brussels sprouts. The name Vitamin K comes from the German word “Koagulationsvitamin.”

Several forms of Phytomenadione (Vitamin K) are used around the world as medicine. But in the U.S., the only form available is Vitamin K1 (phytonadione). Vitamin K1 is generally the preferred form of Vitamin K because it is less toxic, works faster, is stronger, and works better for certain conditions.

In the body, Phytomenadione (Vitamin K) plays a major role in blood clotting. So it is used to reverse the effects of “blood thinning” medications when too much is given; to prevent clotting problems in newborns who don’t have enough Phytomenadione (Vitamin K); and to treat bleeding caused by medications including salicylates, sulfonamides, quinine, quinidine, or antibiotics. Phytomenadione (Vitamin K) is also given to treat and prevent Phytomenadione (Vitamin K) deficiency, a condition in which the body doesn’t have enough Phytomenadione (Vitamin K). It is also used to prevent and treat weak bones (osteoporosis) and relieve itching that often accompanies a liver disease called biliary cirrhosis.

People apply Phytomenadione (Vitamin K) to the skin to remove spider veins, bruises, scars, stretch marks, and burns. It is also used topically to treat rosacea, a skin condition that causes redness and pimples on the face. After surgery, Phytomenadione (Vitamin K) is used to speed up skin healing and reduce bruising and swelling.

Healthcare providers also give Phytomenadione (Vitamin K) by injection to treat clotting problems.

An increased understanding of the role of Phytomenadione (Vitamin K) in the body beyond blood clotting led some researchers to suggest that the recommended amounts for dietary intake of Phytomenadione (Vitamin K) be increased. In 2001, the National Institute of Medicine Food and Nutrition Board increased their recommended amounts of Phytomenadione (Vitamin K) slightly, but refused to make larger increases. They explained there wasn’t enough scientific evidence to make larger increases in the recommended amount of Phytomenadione (Vitamin K).
How effective is it? 
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for Phytomenadione (Vitamin K) are as follows:

Effective for,

  • Treating and preventing Vitamin K deficiency.
  • Preventing certain bleeding or blood clotting problems.
  • Reversing the effects of too much warfarin used to prevent blood clotting.

Insufficient evidence to rate effectiveness for...

  • Weak bones (osteoporosis). So far, research results on the effects of Phytomenadione (Vitamin K) on bone strength and fracture risk in people with osteoporosis don’t agree.
  • Cystic fibrosis.
  • Heart disease.
  • High cholesterol.
  • Spider veins.
  • Bruises.
  • Scars.
  • Stretch marks.
  • Burns.
  • Swelling.
  • Other conditions.
More evidence is needed to rate Phytomenadione (Vitamin K) for these uses.
How does it work?

Phytomenadione (Vitamin K) is an essential vitamin that is needed by the body for blood clotting and other important processes.

Are there safety concerns?

Phytomenadione (Vitamin K) is safe for most people. Most people do not experience any side effects when taking in the recommended amount each day.

Special precautions & warnings:

Pregnancy and breast-feeding: When taken in the recommended amount each day, Phytomenadione (Vitamin K) is considered safe for pregnant and breast-feeding women, but don't use higher amounts without the advice of your healthcare professional.

Kidney disease: Too much Phytomenadione (Vitamin K) can be harmful if you are receiving dialysis treatments due to kidney disease.

Liver disease: Phytomenadione (Vitamin K) is not effective for treating clotting problems caused by severe liver disease. In fact, high doses of Phytomenadione (Vitamin K) can make clotting problems worse in these people.
Are there interactions with medications?


Do not take this combination.

Phytomenadione (Vitamin K) is used by the body to help blood clot. Warfarin (Coumadin) is used to slow blood clotting. By helping the blood clot, Phytomenadione (Vitamin K) might decrease the effectiveness of warfarin (Coumadin). Be sure to have your blood checked regularly. The dose of your warfarin (Coumadin) might need to be changed.

Are there interactions with herbs and supplements?

Coenzyme Q-10

Coenzyme Q-10 is chemically similar to Phytomenadione (Vitamin K) and, like Phytomenadione (Vitamin K), can promote blood clotting. Using these two products together can promote blood clotting more than using just one. This combination can be a problem for people who are taking warfarin to slow blood clotting. Coenzyme Q-10 plus Phytomenadione (Vitamin K) might overwhelm the effects of warfarin and could allow the blood to clot.


There is a concern that tiratricol might interfere with Vitamin K's role in blood clotting.

Vitamin A

In animals, high doses of vitamin A interfere with Vitamin K's ability to clot blood. But it's not known if this also happens in people.

Vitamin E

High doses of vitamin E (e.g. greater than 800 units/day) can make Phytomenadione (Vitamin K) less effective in clotting blood. In people who are taking warfarin to keep their blood from clotting, or in people who have low Phytomenadione (Vitamin K) intakes, high doses of vitamin E can increase the risk of bleeding.

Are there interactions with foods?

There are no known interactions with foods.

What dose is used?

The following doses have been studied in scientific research: 

  • For bleeding disorders such as hypoprothrombinemia: 2.5-25 mg of Vitamin K1 (phytonadione).
  • For counteracting bleeding that can occur when too much of the anticoagulant warfarin is given: 1-5 mg of Phytomenadione (Vitamin K) is typically used; however, the exact dose needed is determined by a lab test called the INR.
There isn't enough scientific information to determine recommended dietary allowances (RDAs) for Phytomenadione (Vitamin K), so daily adequate intake (AI) recommendations have been formed instead: The AIs are: infants 0-6 months, 2 mcg; infants 6-12 months, 2.5 mcg; children 1-3 years, 30 mcg; children 4-8 years, 55 mcg; children 9-13 years, 60 mcg; adolescents 14-18 years (including those who are pregnant or breast-feeding), 75 mcg; men over 19 years, 120 mcg; women over 19 years (including those who are pregnant and breast-feeding), 90 mcg.
  1. Jagannath VA, Fedorowicz Z, Thaker V, Chang AB. Vitamin K supplementation for cystic fibrosis. Cochrane Database Syst Rev. 2011;:CD008482.
  2. Miesner AR, Sullivan TS. Elevated international normalized ratio from vitamin K supplement discontinuation. Ann Pharmacother 2011;45:e2.
  3. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160S-98S.
  4. Rombouts EK, Rosendaal FR. Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 2007;5:2043-8.
  5. Reese AM, Farnett LE, Lyons RM, et al. Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy 2005;25:1746-51.
  6. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007;109:2419-23.
  7. Kurnik D, Lobestein R, Rabinovitz H, et al. Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-depleted patients. Thromb Haemost 2004;92:1018-24.
  8. Sconce E, Khan T, Mason J, et al. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005;93:872-5.
  9. Tamura T, Morgan SL, Takimoto H. Vitamin K and the prevention of fractures (letter and reply). Arch Int Med 2007;167:94-5.
  10. Beulens JW, Bots ML, Atsma F, et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis 2009;203:489-93.
  11. Booth SL, Dallal G, Shea MK, et al. Effect of vitamin K supplementation on bone loss in elderly men and women. J Clin Endocrinol Metab 2008;93:1217-23.
  12. Schurgers LJ, Dissel PE, Spronk HM, et al. Role of vitamin K and vitamin K-dependent proteins in vascular calcification. Z Kardiol 2001;90(suppl 3):57-63.
  13. Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The Rotterdam Study. J Nutr 2004;134:3100-5.
  14. Al-Terkait F, Charalambous H. Severe coagulopathy secondary to vitamin K deficiency in patient with small-bowel resection and rectal cancer. Lancet Oncol 2006;7:188.
  15. Yoshikawa H, Yamazaki S, Watanabe T, Abe T. Vitamin K deficiency in severely disabled children. J Child Neurol 2003;18:93-7.
  16. Schoon EJ, Muller MC, Vermeer C, et al. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut 2001;48:473-7.
  17. Szulc P, Meunier PJ. Is vitamin K deficiency a risk factor for osteoporosis in Crohn's disease? Lancet 2001;357:1995-6.
  18. Duggan P, O'Brien M, Kiely M, et al. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am J Gastroenterol 2004;99:2178-85.
  19. Cockayne S, Adamson J, Lanham-New S, et al. Vitamin K and the prevention of fractures. systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:1256-61.
  20. Rejnmark L, Vestergaard P, Charles P, et al. No effect of vitamin K intake on bone mineral density and fracture risk in perimenopausal women. Osteoporos Int 2006;17:1122-32.
  21. Robert D, Jorgetti V, Leclercq M, et al. Does vitamin K excess induce ectopic calcifications in hemodialysis patients? Clin Nephrol 1985;24:300-4.
  22. Tam DA Jr, Myer EC. Vitamin K-dependent coagulopathy in a child receiving anticonvulsant therapy. J Child Neurol 1996;11:244-6.
  23. Keith DA, Gundberg CM, Japour A, et al. Vitamin K-dependent proteins and anticonvulsant medication. Clin Pharmacol Ther 1983;34:529-32.
  24. Thorp JA, Gaston L, Caspers DR, Pal ML. Current concepts and controversies in the use of vitamin K. Drugs 1995;49:376-87.
  25. Bleyer WA, Skinner AL. Fatal neonatal hemorrhage after maternal anticonvulsant therapy. JAMA 1976;235:626-7.
  26. Renzulli P, Tuchschmid P, Eich G, et al. Early vitamin K deficiency bleeding after maternal phenobarbital intake: management of massive intracranial haemorrhage by minimal surgical intervention. Eur J Pediatr 1998;157:663-5.
  27. Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Supplementation of vitamin K in pregnant women receiving anticonvulsant therapy prevents neonatal vitamin K deficiency. Am J Obstet Gynecol 1993;168:884-8.
  28. Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Increased incidence of neonatal vitamin K deficiency resulting from maternal anticonvulsant therapy. Am J Obstet Gynecol 1993;168:923-8.
  29. MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother 2003;37:510-2.
  30. Vroonhof K, van Rijn HJ, van Hattum J. Vitamin K deficiency and bleeding after long-term use of cholestyramine. Neth J Med 2003;61:19-21.
  31. Van Steenbergen W, Vermylen J. Reversible hypoprothrombinemia in a patient with primary biliary cirrhosis treated with rifampicin. Am J Gastroenterol 1995;90:1526-8.
  32. Kobayashi K, Haruta T, Maeda H, et al. Cerebral hemorrhage associated with vitamin K deficiency in congenital tuberculosis treated with isoniazid and rifampin. Pediatr Infect Dis J 2002;21:1088-90.
  33. Sattler FR, Weitekamp MR, Ballard JO. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med 1986;105:924-31.
  34. Bhat RV, Deshmukh CT. A study of Vitamin K status in children on prolonged antibiotic therapy. Indian Pediatr 2003;40:36-40.
  35. Hooper CA, Haney BB, Stone HH. Gastrointestinal bleeding due to vitamin K deficiency in patients on parenteral cefamandole. Lancet 1980;1:39-40.
  36. Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H. Hypoprothrombobinaemic bleeding associated with ceftriaxone. Lancet 1983;1:1215-6.
  37. Dowd P, Zheng ZB. On the mechanism of the anticlotting action of vitamin E quinone. Proc Natl Acad Sci U S A 1995;92:8171-5.
  38. Davies VA, Rothberg AD, Argent AC, Atkinson PM, Staub H, Pienaar NL. Precursor prothrombin status in patients receiving anticonvulsant drugs. Lancet 1985;1:126-8.
  39. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999;281:235-42.
  40. Schade RWB, van't Laar A, Majoor CLH, Jansen AP. A comparative study of the effects of cholestyramine and neomycin in the treatment of type II hyperlipoproteinemia. Acta Med Scand 1976;199:175-80.
  41. Bendich A, Langseth L. Safety of vitamin A. Am J Clin Nutr 1989;49:358-71.
  42. McDuffie JR, Calis KA, Booth SL, et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002;22:814-22.
  43. Goldin BR, Lichtenstein AH, Gorbach SL. Nutritional and metabolic roles of intestinal flora. In: Shils ME, Olson JA, Shike M, eds. Modern Nutrition in Health and Disease, 8th ed. Malvern, PA: Lea & Febiger, 1994.
  44. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2002. Available at: www.nap.edu/books/0309072794/html/.
  45. Jamal SA, Browner WS, Bauer DC, Cummings SR. Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998;128:829-832.
  46. Shearer MJ. The roles of vitamins D and K in bone health and osteoporosis prevention. Proc Nutr Sci 1997;56:915-37.
  47. Tamatani M, Morimoto S, Nakajima M, et al. Decreased circulating levels of vitamin K and 25-hydroxyvitamin D in osteopenic elderly men. Metabolism 1998;47:195-9.
  48. Weber P. Management of osteoporosis: is there a role for vitamin K? Int J Vitam Nutr Res 1997;67:350-356.
  49. Price PA. Vitamin K nutrition and postmenopausal osteoporosis. J Clin Invest 1993;91:1268.
  50. Yonemura K, Kimura M, Miyaji T, Hishida A. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis.Calcif Tissue Int 2000;66:123-8.
  51. Knapen MH, Hamulyak K, Vermeer C. The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. Ann Intern Med 1989;111:1001-5.
  52. Douglas AS, Robins SP, Hutchison JD, et al. Carboxylation of osteocalcin in post-menopausal osteoporotic women following vitamin K and D supplementation. Bone 1995;17:15-20.
  53. Booth SL, Tucker KL, Chen H, et al. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr 2000;71:1201-8.
  54. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57:1221-7.
  55. Becker GL. The case against mineral oil. Am J Digestive Dis 1952;19:344-8.
  56. Schwarz KB, Goldstein PD, Witztum JL, et al. Fat-soluble vitamin concentrations in hypercholestrolemic children treated with colestipol. Pediatrics 1980;65:243-50.
  57. Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987;2:10-32.
  58. West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 1975;16:93-8.
  59. Conly JM, Stein K, Worobetz L, Rutledge-Harding S. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. Am J Gastroenterol 1994;89:915-23.
  60. Hill MJ. Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev 1997;6:S43-5.
  61. Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;334:1372-3.
  62. Roche, Inc. Xenical package insert. Nutley, NJ. May 1999.
  63. Feskanich D, Weber P, Willett WC, et al. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr 1999;69:74-9.
  64. Hardman JG, Limbird LL, Molinoff PB, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996.
  65. Young DS. Effects of Drugs on Clinical Laboratory Tests 4th ed. Washington: AACC Press, 1995.
  66. Corrigan JJ Jr, Marcus FI. Coagulopathy associated with vitamin E ingestion. JAMA 1974;230:1300-1.
  67. Shearer MJ, Bach A, Kohlmeier M. Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. J Nutr 1996;126:1181S-6S.
  68. Kanai T, Takagi T, Masuhiro K, et al. Serum vitamin K level and bone mineral density in post-menopausal women. Int J Gynaecol Obstet 1997;56:25-30.
  69. Hodges SJ, Akesson K, Vergnaud P, et al. Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res 1993;8:1241-5.
  70. Hart JP, Shearer MJ, Klenerman L, et al. Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosis. J Clin Endocrinol Metab 1985;60:1268-9.
  71. Bitensky L, Hart JP, Catterall A, et al. Circulating vitamin K levels in patients with fractures. J Bone Joint Surg Br 1988;70:663-4.
  72. Nagasawa Y, Fujii M, Kajimoto Y, et al. Vitamin K2 and serum cholesterol in patients on continuous ambulatory peritoneal dialysis. Lancet 1998;351:724.
  73. Iwamoto I, Kosha S, Noguchi S, et al. A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative study with vitamin D3 and estrogen-progestin therapy. Maturitas 1999;31:161-4.
  74. Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists. Hematol Oncol Clin North Am 2000;14:339-53.
  75. Vermeer C, Gijsbers BL, Craciun AM, et al. Effects of vitamin K on bone mass and bone metabolism. J Nutr 1996;126:1187S-91S.
  76. Olson RE. Osteoporosis and vitamin K intake. Am J Clin Nutr 2000;71:1031-2.
  77. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000;15:515-21.
  78. Jie KG, Bots ML, Vermeer C, et al. Vitamin K status and bone mass in women with and without aortic atherosclerosis: a population-based study. Calcif Tissue Int 1996;59:352-6.
  79. Caraballo PJ, Heit JA, Atkinson EJ, et al. Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 1999;159:1750-6.
  80. Matsunaga S, Ito H, Sakou T. The effect of vitamin K and D supplementation on ovariectomy-induced bone loss. Calcif Tissue Int 1999;65:285-9.
  81. Ellenhorn MJ, et al. Ellenhorn's Medical Toxicology: Diagnoses and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams & Wilkins, 1997.
  82. McKevoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.


This information is provided for reference only and not a replacement for and should only be used in conjunction with full consultation with a registered medical practitioner. It may not contain all the available information you require and cannot substitute professional medical care, nor does it take into account all individual circumstances. Although great effort has been made to ensure content accuracy, mph-bd shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise.

Back to top